Trials & Filings

Tesaro Begins Dose-Finding Study

Test rolapitant doses for CINV

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Tesaro, Inc. has initiated an open label, dose-finding and escalation study to evaluate the pharmacokinetics, safety and tolerability of an intravenous (IV) formulation of rolapitant in healthy volunteers. Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). Data from this Phase I study will be used to select the intravenous dose that will be advanced into a subsequent clinical study....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters